Shots:

• Zenith Epigenetics will receive $15M as up front and development milestones- ~$63M commercial milestones and up to 6% royalties on sales in the licensed territories which may reduce to 4% based on certain sales milestones are achieved in the territories
• Newsoara to get rights to develop- commercialize & distribute Zenith’s ZEN-3694 for all indication in China- Hong Kong- Taiwan- and Macau. The license shall expire on a region-by-region basis on the 12^th anniversary of the first commercial sale in licensed territories
• Zenith’s ZEN-3694 is a BET inhibitor- currently being evaluated in P-II study for the treatment of mCRPC & triple-negative breast cancer- administered in combination with other therapies to address resistance and re-sensitize tumors to SOC

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Zenith